This site is intended only for healthcare professionals resident in the Republic of Ireland
Antimicrobial resistance (AMR) is one of the biggest threats to global health today and urgently needs to be addressed. It can affect anyone, of any age, in any country.1
AMR is a silent threat, but it is already here and urgently needs to be addressed. If AMR continues to rise unchecked, minor infections could become life-threatening, serious infections could become impossible to treat and many routine medical procedures could become too risky to perform.1,2
A continued rise in AMR could cause 10 million deaths per year across the globe by 2050 – more than currently die from cancer.2
The COVID-19 pandemic has reinforced a need to invest in diagnostics, infection prevention, surveillance, and stewardship now to help prevent future global health crises. We must take action to help protect our futures.3-5
It is estimated that 1.27 million deaths globally were caused by bacterial AMR in 2019. If no solution is found, this devastating impact is likely to worsen.6
Antimicrobial medicines (antibiotics that target bacteria, antivirals that target viruses, and antifungals that target fungi) are among the most precious medical resources the world has ever known.7
Antibiotics have drastically changed modern medicine, extending the average human lifespan by 23 years.8
Similarities can be drawn between the COVID-19 pandemic and AMR pathogens, including the need for strong public health and preparedness measures.
COVID-19 has threatened the progress made against resistant pathogens and impacted our ability to address AMR, making AMR an even more pressing threat.9
Only three classes of commonly prescribed antifungal drugs currently exist, so antifungal resistance can severely limit treatment options.10
No novel class of antibiotic has been discovered for almost 40 years. There are only 40 to 50 antibiotics in clinical development at present, while thousands of potential immuno-oncology therapies are currently being evaluated. The rate of innovation is insufficient to meet current and future needs.11
Watch our video to learn more about the Haemoassist®2 innovative haemophilia therapy management tool.
[Inclusion of this page will depend on local availability of Haemoassist®2, which is not available in all markets. Please consider during local review and approval process]
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023